GlassScriptPhysician profile
Cara Amy Goodell
NPI 1235498171
$2,000.68
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $1,465.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $445.19 | 2019-2020 | |
| Allergan, INC. | $280.34 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $217.71 | 2019-2020 | |
| Lilly USA, LLC | $184.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.31 | 2019-2020 | |
| Glaxosmithkline, LLC. | $147.73 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.89 | 2019-2020 | |
| Amarin Pharma, INC. | $93.19 | 2020 | |
| Abbvie INC. | $83.93 | 2020 | |
| Sanofi-Aventis U.S. LLC | $63.52 | 2019-2020 | |
| Amgen INC. | $46.74 | 2020 | |
| Ibsa Pharma INC. | $40.66 | 2019-2020 | |
| Astellas Pharma US INC | $36.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $35.14 | 2020 | |
| Amneal Pharmaceuticals LLC | $33.24 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.71 | 2020 | |
| Abbott Laboratories | $12.38 | 2019 | |
| Esperion Therapeutics, INC. | $11.30 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Goodell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.